Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET

Company Participants

DeDe Sheel – Vice President-Investor Relations

Peter Greenleaf – President and Chief Executive Officer

Joe Miller – Chief Financial Officer

Neil Solomons – Chief Medical Officer

Conference Call Participants

Ed Arce – HC Wainwright

Justin Kim – Oppenheimer

Olivia Brayer – Cantor Fitzgerald

Sahil Dhingra – RBC

Operator

Greetings, and welcome to Aurinia Pharmaceuticals Second Quarter 2022 Financial and Operational Results Conference Call. At this time all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host DeDe Sheel, Aurinia's Vice President of Investor Relations. Thank you. You may begin.

DeDe Sheel

Thank you, Doug, and thank you all for joining today's call and webcast to discuss Aurinia's second quarter 2022 financial results. Joining me this morning to lead the call are Peter Greenleaf, President and CEO; Joe Miller, Chief Financial Officer. Dr. Neil Solomons, Chief Medical Officer, will also be available at the conclusion of our prepared remarks for the Q&A portion of the call. This morning we issued a press release announcing our financial results and recent operational highlights and filed our quarterly report on Form 10-Q. For more information, please refer to our filings with the U.S. SEC, which are available on our website at auriniapharma.com.

During this call, we may make forward-looking statements based on our current expectations. These forward-looking statements are subject to a number of significant risks and uncertainties, and our actual results may differ materially. For discussion of factors that could affect our future financial results and business, please refer to the disclosures in our press release and our quarterly report on Form 10-Q, along with our 10-K and all of our recent filings with the SEC and Canadian Securities Authorities. Please note that all statements made during today's call are current as of today, August 04, 2022, unless otherwise noted and are based upon information currently available to us at this time. Except as required by law, we assume no obligation to update any such statements.

Let me now turn the call over to Aurinia's President and CEO, Peter Greenleaf. Peter?

Peter Greenleaf

Thanks, DeDe, and thanks to everyone for joining us today. On the call today, I'll start with a review of our commercial business, including LUPKYNIS performance in the second quarter and the trends we're seeing for the product entering the second half of the year. After that, I'll discuss the recent positive opinion by the CHMP of the EMA putting us on the verge of gaining approval for LUPKYNIS in Europe. I'll also cover the additional ongoing clinical work to reinforce LUPKYNIS benefits for patients and briefly discuss recent events related to our intellectual property. Finally, I'll provide a quick update on our R&D pipeline and then turn the call over to Joe to provide more details on the second quarter financial results and our overall financial position.